# Vulnerable Patient Meeting

# 23-25 JUNE Stresa-Italy





### OUTLINE

### DAY 1

DAY 3

### Basics

2

- Exploring inflammation-based targets in Atherosclerosis
- Translational Science in the Vulnerable Plaque and Vulnerable Patient
- Imagenetics/Imagomics
- Special lectures

### DAY 2 Mechanisms and Imaging

- Non-invasive imaging
- Intravascular Imaging on LRP
- Standalone intravascular imaging
- Advances in hybrid intravascular imaging
- Computational fluid dynamic analysis -2
- Early stage development in cardiovascular disease

### Treatment

- Debate: ASPIRIN way out or renaissance?
- After plaque rupture, Post-sudden death, most vulnerable patient
- Treating the Vulnerable Plaque Systemic Therapy
- Systemic Treatment
- Last debate





3

| 08:00 | Welcome words<br>Patrick W. Serruys  |
|-------|--|
| 08.10 | Exploring inflammation-based targets in Atherosclerosis<br>Naïve Question:<br>Which inflammatory target should we focus on?<br>Chairmen: Martin Bennett and Ranil De Silva |
| 08:10 | Key note lecture: ABC of immune system in atherosclerosis Jon Laman  |
| 08:25 | IL1 and IL6 biology and translation Wolfgang Koenig  |
| 08:35 | Evaluation of shear stress and strain in atherosclerotic pig<br>coronary arteries - towards predictive models of advanced<br>plaque formation<br><b>Ranil De Silva</b>     |
| 08:45 | Takayasu arteritis as a biological testing ground for atherosclerosis: Novel targets in inflammation <b>Justin Mason</b>   |
| 08:55 | Mechanistic aspects of perivascular fat in atherosclerosis<br>Antoniades Charalambos   |
| 09:05 | The humoral immune system as a target in atherosclerosis <b>Ramzi Khamis</b>   |
| 09:15 | Discussion   |

### 09:50 Coffee break

| 10:20 | Translational Science in the Vulnerable Plaque and Vulnerable<br>Patient<br>Chairmen: Justin Mason and Amir Lerman |
|-------|--|
| 10:20 | ABC of Translational Molecular targeting of atherosclerosis <b>Ramzi Khamis</b>                                    |
| 10:30 | Adipose tissue and atherosclerosis on MSCT<br>Antoniades Charalambos   |



| 10:40 | Vascular smooth muscle cell death, autophagy and senescence<br>in Atherosclerosis<br><b>Martin Bennett</b>     |
|-------|--|
| 10:50 | Accelerated atherosclerosis related to systemic inflammatory disease and potential targets <b>Justin Mason</b> |
| 11:00 | Lipid profile in preclinical model and its impact on treating atherosclerosis <b>Ayla Hoogendoorn</b>          |
| 11:10 | What's new in vulnerable plaque pathology?<br><b>Michael Joner</b>   |
| 11:20 | Association between oxidation modified lipoproteins and atherosclerosis in psoriasis <b>Nehal N. Mehta</b>     |
| 11:30 | Discussion   |

#### 12:10 Lunch

| 13:50 | Imagenetics/Imagomics<br>Naïve question:<br><i>Can we combine -omics and cardiac imaging to refine</i><br><i>prediction of vulnerable patient?</i><br>Chairmen: Wolfgang Koenig and Ramzi Khamis |
|-------|--|
| 13:50 | More effective LDL-C lowering for primordial prevention, even in individuals conventionally considered at optimal risk." Javier Sanz   |
| 14:00 | Genomics and phenotypics of immune cell subsets Jon Laman  |
| 14:10 | Biomarker based risk model to predict cardiac mortality in stable<br>coronary artery disease<br>Lars Wallentin   |
| 14:20 | Predictive value of proteomics for plaque morphology <b>Wolfgang Koenig</b>  |
| 14:30 | Artificial Intelligence in the context of disease prevention: digital biomarkers<br>Amir Lerman  |

### **DAY 1** / SUNDAY / JUNE 23, 2019

5



| 14:40        | Identification of Vulnerable Plaque by NIR spectroscopy: an FDA approved imaging marker <b>James Muller</b>  |
|--------------|--|
| 14:50        | Nuclear imaging of inflammation targets<br><b>Kim van der Heiden</b>   |
| 15:00        | Combination of Lipodomics and imaging for lipid profiling of atherosclerosis: MALDI results <b>Gijs van Soest</b>                                      |
| 15:10        | Discussion   |
| 15:50        | Coffee Break   |
|              |  |
| 16:20        | Special lectures<br>Chairmen: Amir Lerman and James Muller   |
| <b>16:20</b> |  |
|              | <b>Chairmen: Amir Lerman and James Muller</b><br>Pollution, Tobacco, nicotine substitutes and the environment<br>Potential Impact on Vulnerable Plaque |

17:00 Adjourn

# DAY 2 Monday June 24, 2019 6

| 08:00 | Non-invasive imaging<br>Technical Corner:<br>Advance in Cardiac MSCT<br>Chairmen: Daniele Andreini and Bon-Kwon Koo  |
|-------|--|
| 08:00 | Future of interventional guidance<br>Nicolas Foin  |
| 08:10 | Update from GE<br><b>Paul Deak</b>   |
| 08:20 | Update from HeartFlow<br>Charles Taylor  |
| 08:30 | Artificial intelligence and imaging Wiro Niessen   |
| 08:40 | Discussion   |
| 08:55 | Non-invasive imaging<br>Technical Corner:<br>Cardiac MSCT for Vulnerable Plaque detection<br>Chairmen: Patrick W. Serruys and Ton van der Steen                                  |
| 08:55 | ABC of "vulnerable" plaque in MSCT<br><b>Daniele Andreini</b>  |
| 09:05 | Deep learning in coronary imaging, from the lumen, the vessel wall, the plaque to the automatic Syntax Score <b>Michiel Schaap</b>   |
| 09:15 | Incremental value of FFRCT on prediction of future event.<br>Emerald II: an update<br><b>Bon-Kwon Koo</b>  |
| 09:25 | FFRCT guidance in diagnosis and treatment of suspected CAD <b>Gregg W. Stone</b>   |
| 09:35 | CTCA for assessing the effect of emerging therapies targeting atherosclerosis <b>Yoshi Onuma</b>   |
| 09:45 | Emerging PET tracers for assessing coronary artery inflammation <b>Jason Tarkin</b>  |
| 09:55 | <b>Discussion</b><br>Diagnostic angiography is at dismal and MSCT is one stop shop<br>imaging tool for CAD – from asymptomatic patients to 3VD, for<br>planning of PCI and CABG. |

### DAY 2 / MONDAY / JUNE 24, 2019

7



10:15 Coffee Break

| 10:35 | Intravascular Imaging on LRP<br>Chairmen: Christos Bourantas and Akiko Maehara   |
|-------|--|
| 10:35 | Basics and new developments of NIR-Spectroscopy Technology including newest changes in catheter <b>Cherry Greiner</b>  |
| 10:45 | NIR-Spectroscopy and Intravascular Ultrasound to Detect<br>Vulnerable Plaques And Vulnerable Patients: Insights From The<br>Lipid-rich Plaque (LRP) Study<br><b>Carlo Di Mario</b>                           |
| 10:55 | What are the implication of LRP study on the PROSPECT II and PREVENT studies <b>Gregg W. Stone</b>   |
| 11:05 | <b>Discussion</b><br>Are we satisfied with the diagnostic capability of intravascular<br>imaging to detect VP?   |
| 11:15 | Standalone intravascular imaging<br>Chairmen: Yoshi Onuma and Ton van der Steen  |
| 11:15 | Reclassification of Plaque rupture and erosion in relationship<br>with healed plaque<br><b>Akiko Maehara</b>   |
| 11:25 | Applications of intravascular imaging in vulnerable plaques<br>detection: An expert consensus document of the European<br>Association of Percutaneous Cardiovascular Interventions<br><b>Gulio Guagliumi</b> |
| 11:35 | Advances in OCT imaging - Attenuation compensated, polarized OCT, micro OCT <b>Brett Bouma</b>   |
| 11:45 | Super fast OCT<br><b>Ton van der Steen</b>   |
| 11:55 | Discussion   |
| 12:15 | Lunch  |

# DAY 2 Monday June 24, 2019 8

| 13:35 | Advances in hybrid intravascular imaging<br>Chairmen: Ton van der Steen and James Muller   |
|-------|--|
| 13:35 | Miniature NIRF-IVUS system<br>Farouc Jaffer  |
| 13:45 | SpectraWAVE: NIRS-OCT<br>Gregg W. Stone  |
| 13:55 | Inflammations and DCBs, and a new anti restenosis – insights<br>from NIRF-OCT<br><b>Farouc Jaffer</b>  |
| 14:05 | CONAVI : IVUS-OCT (First-in-man)<br><b>Brian Courtney</b>  |
| 14:15 | TERUMO : IVUS -OCT<br>Yoshi Onuma  |
| 14:25 | IVUS- photoacoustic imaging<br><b>Gijs van Soest</b>   |
| 14:35 | Discussion   |
| 14:55 | Computational fluid dynamic analysis -2<br>Naïve question:<br>What is the impact of biomechanics on biology?<br>Chairmen: Jolanda Wentzel and Peter Stone  |
| 14:55 | <b>Keynote lecture:</b> Change in paradigm of vulnerable plaque: from plaque rupture to erosion, a computational fluid dynamic analysis <b>Steve White</b> |
| 15:10 | ABC of biomechanical lexicon and atherosclerosis based on the<br>European expert consensus<br><b>Frank Gijsen</b>  |
| 15:20 | Link between inflammation, senescence, apoptosis and shear stress <b>Paul Evans</b>  |
| 15:30 | CFD meet Large Data: Mechanosensitive microRNA families regulate mechanotransduction <b>Rob Krams</b>  |
| 15:40 | Stents, shear stress and endothelium Paul Evans  |
| 15:50 | Discussion   |



[16:10] Coffee Break

## DAY 2 / MONDAY / JUNE 24, 2019

9



| 16:30 | Early stage development in cardiovascular disease<br>Naïve question:<br>Are we ready for prime time of endothelial shear stress?<br>Chairmen: Ranil De Silva and Frank Gijsen |
|-------|---|
| 16:30 | Spatial relationships among local shear stress, MLA, and NIRS<br>lipid signal in patients with CAD: Implications for individual<br>plaque destabilization                     |
|       | a. From Rotterdam<br>Jolanda Wentzel  |
| 16:40 | b. From Boston<br><b>Peter Stone</b>  |
| 16:50 | Emerging concepts of non-invasive calculation of local<br>endothelial shear stress by coronary computed tomography<br>angiography<br><b>Peter Stone</b>                       |
| 17:00 | Role of multidirectional shear stress on atherosclerotic disease progression a sub-analysis of the IBIS4 study <b>Christos Bourantas</b>                                      |
| 17:10 | Plaque stress and plaque vulnerability insights from the<br>PROSPECT study<br><b>Martin Bennett</b>   |
| 17:20 | Colocalization of Mechanical stress and plaque rupture <b>Ali Akyildiz</b>  |
| 17:30 | Shear Stress in cathlab to guide PCI, implication of strut<br>thickness and deformations<br><b>Ryo Torii</b>  |
| 17:40 | Shear stress and coronary remodeling, 3 years after PCI<br>(ABSORB II)?<br><b>Patrick W. Serruys</b>  |
| 17:50 | Return of local treatment: Bioresorbale stent and coronary<br>hemodynamics<br>Javier Escaned  |
| 18:00 | 3D-QCA software makes on-line shear stress feasible   |
|       | a. Medis approach<br><b>Hans Reiber</b>   |
| 18:10 | b. PIE medical approach<br>Jean-Paul Aben   |

### DAY 2 Monday June 24, 2019 10

#### 18:20 **Debate**

Debate

Naïve Questions: Which imaging modality, which parameters, at which time point is the most relevant to detect vulnerable plaque and predict clinical events? Do the current imaging parameters (surrogate endpoints) reflect the clinical effect of therapeutic agent?

18:50 Adjourn

## DAY 3 Tuesday June 25, 2019 11

| 08:00 | Debate: ASPIRIN way out or renaissance?<br>Naïve Questions:<br>Do we need aspirin to prevent event of vulnerable patient?<br>- Should we continue to use aspirin for primary prevention?<br>- Should we continue to use aspirin for 2nd prevention after<br>cardiovascular events?<br>- Should we continue to use aspirin after PCI?<br>- Is there any role for new formulation of aspirin?<br>Chairmen: Yoshi Onuma and Amir Lerman |
|-------|--|
| 08:00 | The best strategy for the use of aspirin in the primary prevention<br>of cardiovascular disease may simply be to prescribe a statin<br>instead<br><b>Yoshi Onuma</b>   |
| 08:10 | A Critical Appraisal of Aspirin in Secondary Prevention. Is Less<br>More?<br><b>Giuseppe Gargiulo</b>  |
| 08:25 | Aspirin is on the way out for post-PCI antiplatelet therapy:<br>Insights from the Global Leaders and ASET?<br><b>Patrick W. Serruys</b>  |
| 08:40 | What will we see in the Twilight? Sneak peak in the TWILIGHT<br>trial<br><b>Roxana Mehran</b>  |
| 08:55 | Renaissance of aspirin will be achieved with a new, safer and more reliable formulation <b>Makis Deliargyris</b>   |
| 09:10 | Debate: ASPIRIN way out or renaissance?  |
| 09:45 | Coffee Break   |
| 10:15 | After plaque rupture, Post-sudden death, most vulnerable<br>patient<br>Chairmen: Patrick W. Serruys and Christos Bourantas   |
| 10:15 | Supersaturated oxygen for treatment of acute myocardial infarction <b>Gregg W. Stone</b>   |
| 10:25 | Landscape of acute mechanical circulatory support<br><b>Susanna Price</b>  |



| 10:35 | Structure-function relationships in the post-MI remodelling heart<br>-insights from combined diffusion and strain cardiovascular<br>magnetic resonance<br><b>Ranil De Silva</b>      |
|-------|--|
| 10:45 | Rationale and landscape for right heart support (PERKAT,<br>Impella RP, TandemLife Protek Duo and Renal Guard)<br><b>Osama Soliman</b>   |
| 10:55 | Clinical experience of Impella from Italian Registry <b>Alaide Chieffo</b>   |
| 11:05 | Discussion   |
| 11:30 | Treating the Vulnerable Plaque – Systemic Therapy<br>Naïve question:<br>What is the role of DOACS to manage residual thrombotic risk?<br>Chairmen: Dorian Haskard and Gregg W. Stone |
| 11:30 | Special lecture: Implications of gut microbiome for cardiovascular disease <b>Thomas Luscher</b>   |
| 11:40 | ABC of Thrombosis and Bleeding (Occlusion and Lysis Time) Thomas Luscher   |
| 11:50 | Discussion   |
| 12:00 | Lunch  |
| 13:30 | Systemic Treatment<br>Naïve question 1:<br>What is the role of immunomodulating agent in management of<br>vulnerable plaque?<br>Chairmen: Ramzi Khamis and Gregg W. Stone            |
| 13:30 | ABC of inflammation as target of therapy in atherosclerosis <b>Thomas Luscher</b>  |
| 13:40 | Update on rheumatological treatments for atherosclerosis – IL6,<br>IL1, Feboxustat and JAK inhibitors<br><b>Dorian Haskard</b>   |
| 13:50 | CANTOS and CIRT – successful proof of concept, but why no<br>clinical adoption? Lessons learnt for developmental pathway of<br>new agent<br><b>Wolfgang Koenig</b>                   |

14:00 **Discussion** 

### DAY 3 / TUESDAY / JUNE 25, 2019



13

| 14:20 | Naïve question 2:<br>Which patient, when, how long and at which cost do we need<br>to allow PCSK-9?<br>Chairmen: Ranil de Silva and Wolfgang Koenig |
|-------|---|
| 14:20 | Rationale for PCSK9 inhibition in ACS (and atherosclerosis?) <b>Thomas Luscher</b>  |
| 14:30 | Answers from ODYSSEY, FOURIER and GLAGOV trials Wolfgang Koenig   |
| 14:40 | Answers from ORION trials David Kallend   |
| 14:50 | New cholesterol modifying agent -1 What do we expect from<br>Bempedoic Acid?<br><b>Alberico L. Catapano</b>   |
| 15:00 | New cholesterol modifying agent -2 What do we expect from apabetalone? <b>Norman Wong</b>   |
| 15:10 | Discussion  |

**15:40** Coffee Break

#### 16:10 Last debate

Open session: What was new? Summary of each session/day (6 chairmen) x 3 min Talks (1 slide) followed by discussion... Chairmen: Patrick W. Serruys and Yoshi Onuma

Adjourn





fostering discoveries

### **GENERAL INFORMATION**

#### **DATES & PLACE**

The Meeting will be held June 23, 24 and 25, 2019, at the Regina Palace Hotel, in Stresa Lago Maggiore, Italy.

Perhaps more than any other Lake Maggiore town, Stresa, with a ringside view of sunrise over the lake, captures the lake's prevailing air of elegance and bygone decadence. This is most evident in the string of belle époque confections along the waterfront, a legacy of the town's easy access from Milan, which has made it a favourite for artists and writers since the late 19th century. The water front promenade offers excellent views of the surrounding, the mountains, and the Borromean islands in the lake.

#### VENUE

REGINA PALACE, STRESA 29, Corso Umberto I, 28838 Stresa VB, Italy Tel: <u>+39 0323 936936</u> | Fax +39.0323.936666 <u>http://www.reginapalace.it/en</u> | The Regina Palace is located in Stresa.

#### SCIENTIFIC PRESENTATIONS

The Meeting room will be equipped with Screen, Data Video Projector for Microsoft Power Point presentations, Note pads, pens and laser pointers. Please download your presentation at the meeting secretariat in advance (preferably the day before) and fill in the relevant presenter material form.

#### **TRANSFER SERVICES FROM/ TO AIRPORT**

Transfer services will be available to/from Malpensa and Linate airport according to your flight itinerary. Kindly note, that there will be a transfer service arranged for you upon your arrival and departure. Pick-up time for your departure transfer will be 3hrs prior your flight departure to Malpensa airport and 3hrs and 30mns prior your flight departure to Linate airport.

#### **MEETING SECRETARIAT & OFFICIAL TRAVEL AGENCY**

The Meeting's Secretariat will operate during meeting hours.

ERA Ltd. 17 Asklipiou Str., 106 80, Athens, Greece T.: +30 210 3634944 | F.: + 30 210 3631690 | E.: info@era.gr | W.: www.era.gr





fostering

**SPECIAL THANKS TO** 









Recovering hearts. Saving lives.

1FD



















APHA INC.



